Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Xin GAO, MD
Fudan University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Department of Endocrinology and Metabolism,shanghai Clinical Center of Diabetes,shanghai Institute of Diabetes,the Sixth People'S Hospital Affiliated To Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
- Department of Endocrinology and Metabolism,the Fifth People'S Hospital，fudan University
Shanghai, Shanghai Municipality, China
- Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University,
Shanghai, Shanghai Municipality, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2008
- Primary completion
- 31 Aug 2011
- Completion
- 31 Aug 2011
- Last update posted
- 5 Jun 2012
- Registered enrollment
- 184
- Registry id
- NCT00633282
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.